How Does Entrectinib Work? Mechanism of Action Explained in Plain English

Understanding how your cancer medication works can help you feel more in control of your treatment. Entrectinib (Rozlytrek) works very differently from traditional chemotherapy — it's a targeted therapy that blocks specific proteins that cancer cells depend on to survive. Here's a plain-English explanation of the science.

What Are Kinases and Why Do They Matter in Cancer?

Your cells use proteins called kinases as molecular "switches" to control cell growth, division, and survival. In healthy cells, these switches turn on and off in a controlled way. But in some cancers, kinase genes become abnormally rearranged ("fused" with other genes), creating mutant proteins that are permanently switched ON — constantly signaling the cell to grow and divide, even when it shouldn't. This is the foundation of what drives certain rare cancers.

What Gene Fusions Does Entrectinib Target?

Entrectinib is specifically designed to block three types of abnormal fusion kinases:

TrkA, TrkB, and TrkC (Tropomyosin Receptor Kinases A, B, and C): These are encoded by the NTRK1, NTRK2, and NTRK3 genes. When these genes fuse with other genes, the resulting abnormal Trk proteins drive tumor growth in a wide variety of solid tumors across different organs.

ROS1 (C-ros oncogene 1): When the ROS1 gene fuses with partner genes, it creates an abnormal protein that drives tumor growth, particularly in non-small cell lung cancer. ROS1 fusions occur in about 1–2% of all NSCLC cases.

ALK (Anaplastic Lymphoma Kinase): Entrectinib also inhibits ALK, another commonly fused kinase in lung cancer and certain lymphomas, though ALK inhibition is not one of its primary FDA-approved indications.

What Is "Oncogene Addiction" and Why Does It Matter?

When a cancer cell becomes dependent on a single abnormal kinase signal to survive and grow, it is said to be "addicted" to that oncogene. This is good news for targeted therapy, because blocking that one signal can be enough to stop the entire tumor. Tumors driven by NTRK or ROS1 gene fusions are highly likely to be addicted to those signals — meaning entrectinib's targeted blockade can be remarkably effective.

How Does Entrectinib Physically Block Tumor Growth?

Entrectinib is a small molecule that enters cells and binds tightly to the ATP-binding pocket of the abnormal TRK, ROS1, or ALK fusion protein. By occupying this binding site, entrectinib prevents the kinase from transferring phosphate groups to downstream signaling molecules. Without this phosphorylation, the cellular cascade that drives tumor growth, proliferation, and survival is cut off. The IC50 values (the concentration needed to inhibit 50% of kinase activity) for entrectinib against these targets are in the range of 0.1 to 2 nanomolar — meaning very small amounts of the drug can have a big effect.

Why Can Entrectinib Treat Brain Metastases?

One of the challenges in treating lung cancer and other solid tumors is that cancer cells sometimes spread to the brain, which is protected by the blood-brain barrier — a highly selective membrane that prevents most large molecules from entering the brain. Many older cancer drugs can't cross this barrier. Entrectinib was specifically engineered to be lipophilic (fat-soluble) enough to cross the blood-brain barrier and exert its activity on brain metastases, which is one of its key clinical advantages over older ROS1 inhibitors like crizotinib.

How Is Entrectinib Different from Chemotherapy?

Traditional chemotherapy attacks all rapidly dividing cells — both cancer cells and healthy cells like hair follicles, gut lining cells, and immune cells. This causes the well-known side effects of hair loss, nausea, and immune suppression. Entrectinib, as a targeted therapy, is designed to specifically block abnormal proteins that are present primarily in cancer cells with the NTRK or ROS1 fusion. This makes it more precise, though it still has side effects because the targeted proteins also play roles in normal tissues (such as the nervous system, which explains why entrectinib causes neurological side effects like dizziness and dysgeusia).

What Happens When Resistance Develops?

Over time, some tumors develop resistance to entrectinib through mutations in the TRK or ROS1 kinase domain that reduce the drug's ability to bind. These are called "on-target" resistance mutations. When resistance occurs, newer-generation TKIs like repotrectinib (Augtyro) — specifically designed to overcome resistance mutations — may be considered. Repeat biopsy or liquid biopsy can help identify the mechanism of resistance.

The Bottom Line

Entrectinib works by precisely blocking the abnormal TRK, ROS1, or ALK fusion proteins that your tumor depends on to grow. It's a targeted, once-daily oral therapy that can cross the blood-brain barrier — a key advantage for patients with or at risk of brain metastases. For a full overview of entrectinib including uses and dosage, see our post What Is Entrectinib? Once prescribed, medfinder can help you locate a specialty pharmacy that can fill your prescription.